Clinical promise of next-generation complement therapeutics

DC Mastellos, D Ricklin, JD Lambris - Nature reviews Drug discovery, 2019 - nature.com
The complement system plays a key role in pathogen immunosurveillance and tissue
homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of …

HUS and atypical HUS

TS Jokiranta - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …

[HTML][HTML] Complement in secondary thrombotic microangiopathy

LMP Palma, M Sridharan, S Sethi - Kidney international reports, 2021 - Elsevier
Thrombotic microangiopathy (TMA) is a condition characterized by thrombocytopenia and
microangiopathic hemolytic anemia (MAHA) with varying degrees of organ damage in the …

Eculizumab in secondary atypical haemolytic uraemic syndrome

T Cavero, C Rabasco, A López… - Nephrology Dialysis …, 2017 - academic.oup.com
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs)
other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients …

Microvascular thrombosis: experimental and clinical implications

MA Bray, SE Sartain, J Gollamudi, RE Rumbaut - Translational Research, 2020 - Elsevier
A significant amount of clinical and research interest in thrombosis is focused on large
vessels (eg, stroke, myocardial infarction, deep venous thrombosis, etc.); however …

COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs?(2017 Grover Conference Series)

F Polverino, BR Celli, CA Owen - Pulmonary Circulation, 2018 - journals.sagepub.com
Chronic obstructive pulmonary disease (COPD) is characterized by chronic expiratory
airflow obstruction that is not fully reversible. COPD patients develop varying degrees of …

Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery

DC Mastellos, ES Reis, D Ricklin, RJ Smith… - Trends in …, 2017 - cell.com
Complement dysregulation underlies several inflammatory disorders, and terminal
complement inhibition has thus far afforded significant clinical gains. Nonetheless, emerging …

[HTML][HTML] Thrombotic microangiopathy associated with monoclonal gammopathy

A Ravindran, RS Go, FC Fervenza, S Sethi - Kidney international, 2017 - Elsevier
Thrombotic microangiopathy (TMA) is a rare disease comprising of a diverse set of disorders
linked by a common histologic finding of endothelial injury. Monoclonal immunoglobulins …

[HTML][HTML] Developments in anti-complement therapy; from disease to clinical trial

CL Harris, RB Pouw, D Kavanagh, R Sun… - Molecular immunology, 2018 - Elsevier
The complement system is well known for its role in innate immunity and in maintenance of
tissue homeostasis, providing a first line of defence against infection and playing a key role …

[HTML][HTML] Inherited kidney complement diseases

M Lemaire, D Noone, AL Lapeyraque… - Clinical Journal of the …, 2021 - journals.lww.com
In the past 20 years, we have witnessed tremendous advances in our ability to diagnose and
treat genetic diseases of the kidney caused by complement dysregulation. Staggering …